The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass
Open accessAbstract
Receptor activator of Nfkb ligand (RANKL) activates, while osteoprotegerin (OPG) inhibits, osteoclastogenesis. In turn a neutralizing Ab against RANKL, denosumab improves bone strength in osteoporosis. OPG also improves muscle strength in mouse models of Duchenne's muscular dystrophy (mdx) and denervation-induce atrophy, but its role and mechanisms of action on muscle weakness in other conditions remains to be investigated. We investigated the effects of RANKL inhibitors on muscle in osteoporotic women and mice that either overexpress RANKL (HuRANKL-Tg+), or lack Pparb and concomitantly develop sarcopenia (Pparb-/-). In women, denosumab over 3 years improved appendicular lean mass and handgrip strength compared to no treatment, whereas bisphosphonate did not. HuRANKL-Tg+ mice displayed lower limb force and maximal speed, while their leg muscle mass was diminished, with a lower number of type I and II fibers. Both OPG and denosumab increased limb force proportionally to the increase in muscle mass. They markedly improved muscle insulin sensitivity and glucose uptake, and decrease anti-myogenic and inflammatory gene expression in muscle, such as myostatin and protein tyrosine phosphatase receptor-γ. Similarly, in Pparb-/-, OPG increased muscle volume and force, while also normalizing their insulin signaling and higher expression of inflammatory genes in skeletal muscle. In conclusions, RANKL deteriorates, while its inhibitor improves, muscle strength and insulin sensitivity in osteoporotic mice and humans. Hence denosumab could represent a novel therapeutic approach for sarcopenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Osteokines, novel exercise-inducible soluble factors secreted by osteocytes, osteo blasts, and osteoclasts, play an important role in the body’s response to exercise, mainly including RANKL [127], sclerostin [128], osteocalcin [129], fibroblast growth factor 23 (FGF23) [95], Wnt3a [130], TGF-β [131], IGF-1 [132], and prostaglandin E2 (PGE2) [133] (Figure 3).”
From Exerkines and Sarcopenia: Unveiling the Mechanism Behind Exercise-Induced Mitochondrial Homeostasis (2025) · cites this paper as [127]
In the citing paper
“Research has shown that RANKL inhibition improves muscle strength and insulin sensitivity in osteoporotic mice and humans through the RANK/RANKL/OPG signaling pathways, potentially representing a new therapeutic avenue for sarcopenia [127].”
From Exerkines and Sarcopenia: Unveiling the Mechanism Behind Exercise-Induced Mitochondrial Homeostasis (2025) · cites this paper as [127]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Hotamisligil, G. S., Peraldi, P., Budavari, A., Ellis, R., White, M. F., & Spiegelman, B. M. (1996) · Science · doi:10.1126/science.271.5249.665 · Cited by 2,630
Aguirre, V., Werner, E. D., Giraud, J., Lee, Y. H., Shoelson, S. E., & White, M. F. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m101521200 · Cited by 1,010
Mechanisms of Disease: is osteoporosis the obesity of bone?
Rosen, C. J., & Bouxsein, M. (2006) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0070 · Cited by 974
Role of RANK ligand in mediating increased bone resorption in early postmenopausal women
Eghbali-Fatourechi, G., Khosla, S., Sanyal, A., Boyle, W. J., Lacey, D. L., & Riggs, B. L. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17215 · Cited by 825 · cited 1×
“Increased expression of receptor activator of nuclear factor kappa-B ligand (RANKL) in postmenopausal women plays a central role in the development of osteoporosis (5).”
Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab
Lacey, D. L., Boyle, W. J., Simonet, W. S., Kostenuik, P. J., Dougall, W. C., Sullivan, J. K., Martín, J. S., & Dansey, R. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3705 · Cited by 698
Trombetti, A., Reid, K. F., Hars, M., Herrmann, F. R., Pasha, E. P., Phillips, E. M., & Fielding, R. A. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3236-5 · Cited by 479
Inflammatory cytokines inhibit myogenic differentiation through activation of nuclear factor‐κΒ
LANGEN, R. C. J., Schols, A. M. W. J., KELDERS, M. C. J. M., Wouters, E. F. �., & Janssen-Heininger, Y. M. W. (2001) · The FASEB Journal · doi:10.1096/fj.00-0463 · Cited by 436
Microbiota depletion promotes browning of white adipose tissue and reduces obesity
Suárez-Zamorano, N., Fabbiano, S., Chevalier, C., Stojanović, O., Colin, D. J., Stevanović, A., Veyrat-Durebex, C., Tarallo, V., Rigo, D., Germain, S., et al. (2015) · Nature Medicine · doi:10.1038/nm.3994 · Cited by 403
Aging in adipocytes: Potential impact of inherent, depot-specific mechanisms
CARTWRIGHT, M., TCHKONIA, T., & KIRKLAND, J. (2007) · Experimental Gerontology · doi:10.1016/j.exger.2007.03.003 · Cited by 318
Kiechl, S. J., Wittmann, J., Giaccari, A., Knoflach, M., Willeit, P., Bözec, A., Moschen, A. R., Muscogiuri, G., Sorice, G. P., Kireva, T., et al. (2013) · Nature Medicine · doi:10.1038/nm.3084 · Cited by 264
Camporez, J.-P. G., Petersen, M. C., Abudukadier, A., Moreira, G. V., Jurczak, M. J., Friedman, G., Haqq, C. M., Petersen, K. F., & Shulman, G. I. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525795113 · Cited by 184
Reproducibility of running time to exhaustion at &OV0312;O2max in subelite runners
Billat, V. L., Renoux, J. C., Pinoteau, J., Petit, B., & Koralsztein, J. P. (1994) · Medicine & Science in Sports & Exercise · doi:10.1249/00005768-199402000-00018 · Cited by 176
Bonnet, N., Conway, S. J., & Ferrari, S. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203085109 · Cited by 149
McCloskey, E. V., Johansson, H., Odén, A., Austin, M., Siris, E. S., Wang, A., Lewiecki, E. M., Lorenc, R. S., Libanati, C. R., & Kanis, J. А. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1606 · Cited by 144
Pharmacological repression of PPARγ promotes osteogenesis
Marciano, D. P., Kuruvilla, D. S., Boregowda, S. V., Asteian, A., Hughes, T., Garcia-Ordoñez, R. D., Corzo, C. A., Khan, T. M., Novick, S. J., Park, H., et al. (2015) · Nature Communications · doi:10.1038/ncomms8443 · Cited by 136
Ominsky, M. S., Li, X., Asuncion, F., Barrero, M., Warmington, K. S., Dwyer, D., Stolina, M., Geng, Z., Grisanti, M. S., Tan, H., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080109 · Cited by 132
Dong, H., Hu, H., Yun, X., Kim, D., Yue, Y.-N., Wu, H., Sutter, A. G., Chavin, K. D., Otterbein, L. E., Adams, D. B., et al. (2014) · Endocrinology · doi:10.1210/en.2013-1667 · Cited by 129
Maurel, D. B., Jähn, K., & Lara-Castillo, N. (2017) · Biomedicines · doi:10.3390/biomedicines5040062 · Cited by 127
Sylow, L., Nielsen, I. L., Kleinert, M., Møller, L. L. V., Ploug, T., Schjerling, P., Bilan, P. J., Klip, A., Jensen, T. E., & Richter, E. A. (2016) · The Journal of Physiology · doi:10.1113/jp272039 · Cited by 114
Exercise: the lifelong supplement for healthy ageing and slowing down the onset of frailty
Viña, J., Rodríguez‐Mañas, L., Salvador‐Pascual, A., Tarazona‐Santabalbina, F. J., & Gómez‐Cabrera, M. C. (2016) · The Journal of Physiology · doi:10.1113/jp270536 · Cited by 113
Hars, M., Biver, E., Chevalley, T., Herrmann, F. R., Rizzoli, R., Ferrari, S., & Trombetti, A. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2878 · Cited by 107
Huang, J. M., Hsu, Y., Mo, C., de Abreu, E. L., Kiel, D. P., Bonewald, L. F., Brotto, M., & Karasik, D. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2200 · Cited by 99
Dufresne, S. S., Dumont, N. A., Boulanger‐Piette, A., Fajardo, V. A., Gamu, D., Kake‐Guena, S. A., David, R. O., Bouchard, P., Lavergne, É., Penninger, J. M., et al. (2016) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00285.2015 · Cited by 77
Novel Genetic Models of Osteoporosis by Overexpression of Human RANKL in Transgenic Mice
Rinotas, V. E., Niti, A., Dacquin, R., Bonnet, N., Stolina, M., Han, C.-Y. E., Kostenuik, P. J., Jurdic, P., Ferrari, S., & Douni, E. K. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2112 · Cited by 73
Myostatin Inhibition Prevents Diabetes and Hyperphagia in a Mouse Model of Lipodystrophy
Guo, T., Bond, N. D., Jou, W., Gavrilova, O., Portas, J., & McPherron, A. C. (2012) · Diabetes · doi:10.2337/db11-0915 · Cited by 68
Brénachot, X., Ramadori, G., Ioris, R. M., Veyrat‐Durebex, C., Altirriba, J., Aras, E., Ljubicic, S., Kohno, D., Fabbiano, S., Clément, S., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02074-2 · Cited by 62
Osteoprotegerin Protects against Muscular Dystrophy
Dufresne, S. S., Dumont, N. A., Bouchard, P., Lavergne, É., Penninger, J. M., & Frenette, J. (2015) · The American Journal of Pathology · doi:10.1016/j.ajpath.2015.01.006 · Cited by 61
Hepatic PTEN deficiency improves muscle insulin sensitivity and decreases adiposity in mice
Peyrou, M., Bourgoin, L., Poher, A.-L., Altirriba, J., Maeder, C., Caillon, A., Fournier, M., Montet, X., Rohner‐Jeanrenaud, F., & Foti, M. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.09.012 · Cited by 59
Lee, D. H., & Goldberg, A. L. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.685164 · Cited by 59
Dufresne, S. S., Boulanger-Piette, A., Bossé, S., Argaw, A., Hamoudi, D., Marcadet, L., Gamu, D., Fajardo, V. A., Yagita, H., Penninger, J. M., et al. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0533-1 · Cited by 59
Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis
Lewiecki, E. M. (2011) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s7727 · Cited by 42
Duan, P., Yang, M., Wei, M., Liu, J., & Tu, P. (2017) · International Journal of Endocrinology · doi:10.1155/2017/8724869 · Cited by 34
TNFα Increases RANKL Expression via PGE2-Induced Activation of NFATc1
Park, H.-J., Baek, K., Baek, J., & Kim, H. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030495 · Cited by 32
Bonnet, N., Biver, E., Chevalley, T., Rizzoli, R., Garnero, P., & Ferrari, S. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3203 · Cited by 29
Mashavi, M., Menaged, M., & Shargorodsky, M. (2017) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000000914 · Cited by 19
Treatment of facioscapulohumeral muscular dystrophy with Denosumab
Lefkowitz, S. S., Lefkowitz, D. L., & Kethley, J. (2012) · American Journal of Case Reports · doi:10.12659/ajcr.882771 · Cited by 15
Dufresne, S. S., Boulanger‐Piette, A., Bossé, S., & Frenette, J. (2016) · Receptors & Clinical Investigation · doi:10.14800/rci.1323 · Cited by 15
Impaired Musculoskeletal Response to Age and Exercise in PPARβ−/− Diabetic Mice
Fu, H., Desvergne, B., Ferrari, S., & Bonnet, N. (2014) · Endocrinology · doi:10.1210/en.2014-1585 · Cited by 13
Jiang, J. G., Shen, G. F., Li, J., Qiao, C., Xiao, B., Yan, H. M., Wang, D. W., & Xiao, X. (2016) · Gene Therapy · doi:10.1038/gt.2016.85 · Cited by 9
Flagged first, then by citations
Cited by
Sorted by citations
RANKL biology: bone metabolism, the immune system, and beyond
Ono, T., Hayashi, M., Sasaki, F., & Nakashima, T. (2020) · Inflammation and Regeneration · doi:10.1186/s41232-019-0111-3 · Cited by 597
Osteosarcopenia: epidemiology, diagnosis, and treatment—facts and numbers
Kirk, B., Zanker, J., & Duque, G. (2020) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12567 · Cited by 535
Sarcopenia, osteoporosis and frailty
Gielen, E., Dupont, J., Dejaeger, M., & Laurent, M. R. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155638 · Cited by 282
Weivoda, M. M., Chew, C. K., Monroe, D. G., Farr, J. N., Atkinson, E. J., Geske, J. R., Eckhardt, B., Thicke, B., Ruan, M., Tweed, A. J., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14003-6 · Cited by 230
The Interplay Between Bone and Glucose Metabolism
Cipriani, C., Colangelo, L., Santori, R., Renella, M., Mastrantonio, M., Minisola, S., & Pepe, J. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00122 · Cited by 202
Metadata
- Authors
- Bonnet, N., Bourgoin, L., Biver, E., Douni, E., & Ferrari, S.
- Affiliations
- University Hospital of Geneva (CH)
- Agricultural University of Athens (GR)
- Corresponding author
- Bonnet, Nicolas
- Venue
- Journal of Clinical Investigation
- Published
- 2019-07-02
- Volume
- 129
- Issue
- 8
- Pages
- 3214-3223
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC6668701
- OpenAlex
- W2945787015
- Cited by
- 314
- References
- 41
- Citations by year
- 2026: 39 · 2025: 48 · 2024: 42 · 2023: 48 · 2022: 45 · 2021: 46 · 2020: 36 · 2019: 10
- FWCI
- 11.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (publishedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Funders
- Swiss National Science Foundation grant (No 3100A0-116633/1)
- European Foundation for the Study of Diabetes (ME1598)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- RANKL inhibition, denosumab, osteoprotegerin, muscle strength, insulin sensitivity, sarcopenia, osteoporosis, PPARδ, muscle atrophy, muscle fiber composition, myostatin, PTEN, skeletal muscle glucose uptake, muscle inflammation, bisphosphonates, osteoclastogenesis
- MeSH terms
- Denosumab, Animals, Bone and Bones, Cell Line, Female, Humans, Insulin Resistance, Male, Mice, Transgenic, Organ Size, Osteoporosis, PPAR-beta, Mice, Osteoprotegerin, RANK Ligand, Muscle Strength, Sarcopenia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
